Cancer Research, Complementary Medicine / 13.09.2024

Disclaimer: Encer is a homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective.

In the diverse and evolving field of complementary and alternative medicine, homeopathy has established a distinct presence. Encer - a homeopathic medicine used for its potential in managing cancer-related fatigue (CRF), a prevalent and debilitating symptom affecting individuals diagnosed with cancer.

What is Encer

Encer is a homeopathic remedy designed with a blend of highly diluted natural substances. Following the homeopathic principle of "like cures like," it is formulated to stimulate the body's self-healing mechanisms. Despite the absence of Encer in mainstream pharmacological references, as it's a concept perhaps more familiar within homeopathic circles, its use is aimed at providing a non-toxic, gentle treatment option for managing the symptoms of cancer and its treatment, including CRF. (more…)
Breast Cancer / 13.09.2024

Editor's note:  Remember to follow your health care providers' instructions regarding regular breast examinations and mammograms.  Don't wait for a sign or symptom of breast cancer to get screened. Breast cancer is one of the most prevalent cancers affecting women worldwide. While it can be a frightening diagnosis, early detection significantly improves treatment outcomes and survival rates. By being aware of the symptoms of breast cancer, individuals can take proactive steps to seek medical attention, ensuring the best possible chance for early intervention. In this article, we’ll walk through the key signs to watch for and the importance of understanding your body.

Understanding Breast Cancer

Before diving into the specific symptoms, it’s essential to have a basic understanding of breast cancer. Breast cancer occurs when cells in the breast begin to grow uncontrollably, forming a tumor that can be felt as a lump or seen on imaging tests. There are several types of breast cancer, but the two most common forms are ductal carcinoma (which starts in the ducts that carry milk to the nipple) and lobular carcinoma (which begins in the lobules where breast milk is produced). (more…)
Author Interviews, Cancer Research / 01.08.2024

MedicalResearch.com Interview with: Dr Meena Rafiq | Academic GP & Clinical Research Fellow FRACGP MRCGP MBBS BSc MSc Epidemiology of Cancer and Healthcare Outcomes (ECHO) Group, UCL Department of General Practice, The University of Melbourne UCL Department of Behavioural Science and Health     MedicalResearch.com: What is the background for this study? What are the main findings? Response: Almost all patients with cancer will first see their GP with symptoms and half of these patients will have vague, non-specific symptoms. As a GP I know it can be challenging to pick up patients with possible cancer in a 10 minute GP appointment, especially if they have vague non-specific symptoms. We know that many of these patients are already having blood tests done by their GP. So, we wanted to see if any of these blood tests could be used to help pick up with patients who see their GP with vague abdominal symptoms like abdominal pain and bloating are most likely to have cancer and need to be urgently referred. (more…)
Author Interviews, Brigham & Women's - Harvard, Genetic Research, JAMA, Karolinski Institute, Prostate Cancer / 05.07.2024

MedicalResearch.com Interview with: Anna Plym PhD Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden Department of Epidemiology, Harvard T. H. Chan School of Public Health Department of Urology, Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts MedicalResearch.com: What is the background for this study? Response: Prostate cancer is one of the leading causes of cancer death among men, with approximately one third of the deaths occurring before the age of 75 years. There is a need for a better understanding of the risk factors for those early deaths. Our previous research has indicated that inherited factors play a major role. (more…)
Hematology, Leukemia / 02.07.2024

bone-marrow-aspirateBone marrow aspiration is a medical procedure where a small amount of the liquid part of your bone marrow is removed for examination. A bone marrow aspirate can be essential in diagnosing and monitoring various conditions affecting your blood cells, such as anemia, leukemia, and infections. Understanding this procedure can provide insight into why your doctor may recommend it and what to expect. During a bone marrow aspiration, your healthcare provider will take a sample using a needle inserted into a larger bone, typically the hip. The process is usually performed alongside a bone marrow biopsy, which involves taking a small amount of solid bone marrow tissue. These procedures can yield valuable information about the health and functionality of your bone marrow. Preparation for bone marrow aspiration involves a few straightforward steps to ensure your comfort and safety. Knowing the potential risks and benefits can help you feel more at ease and prepared for this critical diagnostic tool. (more…)
Author Interviews, Breast Cancer, Colon Cancer, Genetic Research, JAMA / 20.06.2024

MedicalResearch.com Interview with: Dr. Jeremy L. Davis M.D. Surgical Oncologist Center for Cancer Research Dr. Davis’ research focuses on sporadic and inherited forms of stomach cancer. National Cancer Institute   MedicalResearch.com: What is the background for this study? Response: Individuals who are born with a CDH1 gene mutation are at increased risk of developing specific cancers in their lifetime. Those cancers are called diffuse-type gastric cancer and lobular breast cancer. The background that is relevant here is that when mutations in this gene were first identified as the cause of inherited forms of these cancers, the estimated lifetime risk of gastric cancer, for instance, was around 60-83%. Because of this very high risk and because gastric cancer is particularly difficult to treat, many experts recommend prophylactic surgery to remove the stomach. In recent years, as we have seen more families who carry a CDH1 gene mutation, we have also observed that gastric cancer rates did not seem quite as high as those risk estimates would have suggested. We sought to re-evaluate lifetime risk of cancer with a large and diverse cohort of individuals throughout North America. (more…)
ASCO, Author Interviews, Technology / 08.06.2024

MedicalResearch.com Interview with: Frederick Howard MD Assistant Professor of Medicine Section of Hematology / Oncology University of Chicago MedicalResearch.com: What is the background for this study? Response: With the advent of AI language models like ChatGPT, these tools may be used to generate scientific literature or abstracts. Indeed, a survey conducted by Nature in 2023 found that nearly 30% of scientists were using AI tools to aid in the writing of scientific manuscripts. The use of AI in scientific literature can be difficult to identify, and previous studies suggest that human reviewers cannot distinguish between AI generated and human written scientific abstracts. Commercial tools designed to identify AI content may have a higher degree of accuracy, but the optimal approach to applying such tools to detect AI content within scientific literature is uncertain. (more…)
Author Interviews, Biomarkers, Cancer Research, Colon Cancer / 06.06.2024

MedicalResearch.com Interview with: Jorge Moscat, PhD Maria T. Diaz-Meco, PhD Jorge Moscat Maria T. Diaz-Meco, Principal Investigators Moscat & Diaz-Meco Laboratories Department of Pathology and Laboratory Medicine Weill Cornell Medicine New York, NY MedicalResearch.com: What is the background for this study? Would you describe the two different histological premalignant states? Response: Although much effort is devoted to understanding the biology and pathology of established malignant tumors and the formation of metastasis in order to identify new and more efficacious treatment approaches, much less is understood of how tumors initiate from normal cells. This is extremely important because treating incipient benign neoplasia should be easier and less toxic than treated already aggressive and disseminated cancer cells. In the case of colorectal cancer (CRC), routinary colonoscopies might identify still benign lesions that can be either “serrated” or “conventional” but that all present with reduced levels of two proteins called the aPKCs. As the tumor evolves, if the aPKCs are not upregulated, then the cancer becomes very aggressive and with very limited therapeutic options. Our work identifies precisely the initial mechanisms that determine if a benign adenoma would progress towards an aggressive phenotype. A full comprehension of these initial steps will lead to effective preventive therapies to stop cancer before it starts. (more…)
ASCO, Author Interviews, Breast Cancer, Genetic Research / 05.06.2024

MedicalResearch.com Interview with: Rima Patel, MD Assistant Professor, Division of Hematology/Oncology The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai   MedicalResearch.com: What is the background for this study? Response: The 21-gene Oncotype DX Recurrence Score (RS) and 70-gene MammaPrint (MP) assays provide prognostic information for distant recurrence and are used to guide chemotherapy use in hormone receptor (HR)-positive, HER2-negative early breast cancer (EBC). Previous reports have demonstrated racial differences in the prognostic accuracy of the RS. In both the TAILORx and RxPONDER trials, Black women with low genomic risk (RS 0-25) had a higher recurrence risk than White women. In another study using the NCDB database, Black race was associated with worse overall survival in multivariate models including RS. The impacts of race/ethnicity on the MammaPrint assay are unknown. (more…)
ASCO, Author Interviews, Cancer Research, Race/Ethnic Diversity / 05.06.2024

MedicalResearch.com Interview with: Nina Bickell, MD, MPH Associate Director of Community Engaged and Equity Research Co-Leader of the Cancer Prevention and Control Program Co-Director of the Center for Health Equity and Community Engaged Research The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai   MedicalResearch.com: What is the background for this study? Response: Recruiting diverse patients to clinical trials is essential to advance cancer treatments, yet accrual remains low. Efficient recruitment requires the ability identify patients at treatment decision points and determine eligibility for open clinical trials – a time and personnel intensive undertaking. We developed an automated Regular Expressions technology to identify, classify and match patients to clinical trials and overcome the limitations of more resource-intensive technologies like Natural Language Processing (NLP). We created a screener, parser and matcher to: use the electronic health record to identify patients at treatment decision points based on progress notes and imaging reports and classify their cancer type, stage and receptor status; extract and categorize breast, liver and lung cancer trial data based on cancer type, stage, and receptor status from the National Cancer Institute's ClinicalTrials.gov database; pair eligible patients with relevant trials based on stage and receptor status. (more…)
Author Interviews, Colon Cancer, Gastrointestinal Disease, Immunotherapy / 04.06.2024

MedicalResearch.com Interview with: Steven H. Itzkowitz, MD, FACP, FACG, AGAF Professor of Medicine and Oncological Sciences Director of the GI Fellowship Program Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study looked at patients with inflammatory bowel disease (IBD) who had a history of cancer in the past 5 years and asked whether the medications they received for their IBD might have affected their rates of getting future cancer (new or recurrent cancers). Because many of the medicines that are used to treat IBD can affect the immune system in various ways, there has been concern that the medicines might predispose to subsequent cancers. We found that patients who received immunosuppressive medications had a numerically increased risk of subsequent cancer, this was not statistically higher than those who had not been exposed to these medications. While previous studies have looked at this question retrospectively, this is the first report that analyzed this issue prospectively using individuals from the United States.  Moreover, this study represents a multi-institutional collaboration among gastroenterologists at most of the major NYC healthcare systems. (more…)
Author Interviews, Dermatology, Melanoma, Race/Ethnic Diversity / 24.05.2024

MedicalResearch.com Interview with: Andrew F. Alexis, MD, MPH Vice-Chair for Diversity and Inclusion Department of Dermatology Dermatologist Center for Diverse Skin Complexions Weill Cornell Medicine – NY MedicalResearch.com: What are the main types of skin cancer?  Is the incidence changing? Response: The 3 main types of skin cancer are melanoma, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Skin cancer is the most common cancer in the United States1 and 1 in 5 Americans will develop skin cancer in their lifetime. (2) The overall incidence has changed as follows: • Melanoma: Rates doubled over past 30 years from 1982 to 2011.3 It differs by age group. o Adolescents and adults age 30 and younger: incidence rate is declining o Older age groups (e.g. 80 and older): incidence rate is increasing • Squamous Cell Cancer: o Incidence increased 263% between 1976-1984 and 2000-20104 • Basal Cell Cancer: o Incidence increased 145% between 1976-1984 and 2000-20104 (more…)
Cancer Research, Environmental Risks / 22.05.2024

Per- and poly-fluoroalkyl substances (PFAS) are a class of compounds utilized in a variety of industrial and commercial applications, such as firefighting foams and military equipment. Recent research has raised concerns about the possible health implications of PFAS exposure, specifically its association with testicular cancer. Firefighters and military personnel are particularly vulnerable owing to work exposure to PFAS-containing chemicals. This article explores the connection between PFAS exposure and testicular cancer, focusing on the impact on firefighters and military personnel. It will also discuss the legal recourse available for these individuals through AFFF lawsuits. (more…)
Author Interviews, Cancer Research, University of Pittsburgh / 09.05.2024

MedicalResearch.com Interview with: Roderick J. O’Sullivan PhD Associate Professor Department of Pharmacology and Chemical Biology UPMC Hillman Cancer Center University of Pittsburgh Pittsburgh, PA MedicalResearch.com: What is the background for this study? Response: For a few years, my group has had the good fortune of collaborating with Dr. Ivan Ahel. Ivan is a world leader in the field of ADP-ribosylation. His work has identified major gaps in our understanding of ADP-ribosylation. This includes his lab discovering that DNA bases can be ADP-ribosylated in bacteria and that a poorly characterized enzyme known as TARG1 could be involved in that process. In discussing this work with Ivan, we were confident that DNA ADP-ribosylation also exists in human cells and that showing this could be pretty important. The problem was that identifying a part of the genome where it might be present, so we could study it, was not so obvious and challenging. But we had a hunch that telomeres could be one part of the genome where it could happen!! Telomeres are really special structures located at the ends of each human chromosome. They demarcate the physical end of each chromosome and prevent chromosomes from becoming entangled – which if it happens, is catastrophic for cells. Our hunch was based on the evidence from other studies that telomeres are natural targets of PARP1, the enzyme that catalyzes most of the ADP-ribosylation in human cells. I then discussed this idea with Anne Wondisford, a medical scientist trainee in the lab, who liked the idea and designed a series of experiments to test it. (more…)
Author Interviews, Breast Cancer, JAMA, USPSTF / 01.05.2024

MedicalResearch.com Interview with: Wanda K. Nicholson, M.D., M.P.H., M.B.A. Senior Associate Dean for Diversity, Equity, and Inclusion Professor of Prevention and Community Health Milken Institute School of Public Health George Washington University Dr. Nicholson was appointed chair of the U.S. Preventive Services Task Force in March 2024. She served as vice chair from March 2022 to March 2024 and as a member of the Task Force from January 2009 through December 2013. MedicalResearch.com: What is the background for this study? What are the main findings? Response: Breast cancer is the second most common cancer and the second most common cause of cancer deaths for women in the U.S. After reviewing the latest science, the Task Force recommends screening all women for breast cancer every other year starting at age 40 and continuing through age 74. This new approach has the potential to save nearly 20 percent more lives from breast cancer and has even greater potential benefit for Black women, who are much more likely to die from breast cancer. (more…)
AACR, Author Interviews, Biomarkers, Breast Cancer, Cancer Research / 11.04.2024

MedicalResearch.com Interview with: RJ Tesi M.D. CEO and Founder of INmune Bio MedicalResearch.com: What is the background for this study? What are the main findings?
  • MUC4 expression by high-risk breast cancer (HER2+ or TNBC) is a biomarker that predicts resistance to therapy and an increased risk a metastasis. MUC4 expression can be determined at time of biopsy and therapeutic decisions should be adjusted to optimize the chance of response to first line therapy.
This biomarker is easily determined using immunohistochemistry in the diagnostic breast biopsy tissue similar to testing for HER2 expression. Testing for MUC4 can be easily added to the current panel of routine stains obtained at the time of the diagnostic biopsy. Knowing MUC4 status in women with high-risk breast cancer will improve results.
  • Soluble TNF causes the up regulation of immune checkpoint proteins of cells of the TME. This includes CD47 and SIRPa on tumor based macrophages and CTLA4, PD1, LAG3 and TIGIT on T cells in the TME. INB03 is a pan immune checkpoint modulator. Treatment with INB03 downregulates all immune checkpoint proteins on the cells. Downmodulation of all immune checkpoint proteins improves response to immunotherapy.
Currently, monoclonal antibodies targeting immune checkpoint proteins are a mainstay of cancer therapy and cancer drug development. These strategies target one immune checkpoint protein at a time. To date, combination therapy targeting two immune checkpoint proteins has been tried (e.g.: anti-PD1 and anti-CTLA4 combination therapy) with mixed results. Combination immune checkpoint strategies may increase therapeutic response but increase toxicity. INB03 downregulates all immune checkpoint proteins. This is equivalent to giving a patient a 6 antibody cocktail – something that cannot be done in man. As expected, decreased immune checkpoint expression improves response to therapy by converting immunotherapy resistant tumors to immunotherapy sensitive tumors.
  • In TNBC, MUC4 expression predicts both resistance to anti-PD1 therapy and increased risk of distant metastasis. Treatment with INB03 decreases expression of proteins associated with tumor metastasis, decreases the number of metastasis and improves response to anti-PD1 therapy. Early use of INB03 may prevent distal disease and improve tumor control.
(more…)
Author Interviews, Cancer Research, Prostate, Prostate Cancer, Urology, Vaccine Studies / 08.04.2024

MedicalResearch.com Interview with: Sujit Nair, PhD Director of GU Immunotherapy Research Department of Urology Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? How is the vaccine obtained? Response: https://classic.clinicaltrials.gov/ct2/show/NCT03262103 Dr. Tewari is the treating physician and clinical lead on the study.  This is a phase I, open-label, clinical trial (NCT03262103) using a dose escalation strategy in 12 patients diagnosed with clinically localized prostate cancer with plans for surgery. The investigational agent used in the trial is Poly-ICLC, an immune modulator developed by ONCOVIR. Poly-ICLC is a double-stranded RNA that mimics viral activity, thereby stimulating the immune response. (more…)
Author Interviews, Breast Cancer, Radiology / 28.03.2024

MedicalResearch.com Interview with: Yolanda Bryce, MD Director, Interventional Radiology Residency Program Memorial Sloan Kettering Cancer Center New York   MedicalResearch.com: What is the background for this study? For whom would this treatment be indicated? Response: The standard of care for local breast cancer includes surgery, however many patients are poor surgical candidates or refuse surgery. I use cryoablation to treat this population. (more…)
Author Interviews, Cancer Research, Prostate Cancer, Radiology / 25.03.2024

MedicalResearch.com Interview with: Steven S. Raman, M.D., FASR, FSIR Professor of Radiology, Urology and Surgery David Geffen School of Medicine UCLA MedicalResearch.com: What is the background for this study? Would you describe the TULSA technique? Response: Prostate cancer is the most common solid organ cancer in men.  Currently whole gland ablation relies on surgery or radiation both of which have high rates of impotence and incontinence but also have up to a 30% rate of post therapy recurrence. TULSA is a new minimally invasive technique to treat PCa under MRI guidance with both near continuous whole gland MRI imaging and MRI thermometry to make sure the extent of lethal heating over 55 degrees Celsius is known.  (more…)
Addiction, Author Interviews, Cancer Research, Cannabis / 23.03.2024

MedicalResearch.com Interview with: Brian J. Piper, PhD Associate Professor of Neuroscience Geisinger Commonwealth School of Medicine Scranton PA 18411 MedicalResearch.com: What is the background for this study? Response: Many cancer patients use marijuana to treat pain, nausea, or anxiety, often without communicating this with their health care providers. Two observational studies (1, 2) from a single institution in Israel purporting to find a dangerous drug interaction between medical cannabis and immunotherapy have been cited hundreds of times, including by clinical practice guidelines. The cannabinoid CB2 receptor is found on immune tissues so it is biologically possible that marijuana could make immunotherapies like nivolumab less effective. However, there were anonymous reports on PubPeer (3-5) of many irregularities in the data-analysis. If there were unappreciated differences on other important variables at baseline besides subsequent cannabis use, this could change the interpretation of these influential reports (1, 2). This investigation involved attempting to repeat and verify the data-analysis. (more…)
Author Interviews, Colon Cancer, JAMA / 19.03.2024

MedicalResearch.com Interview with: Eric Montminy MD Interventional Endoscopist Cook County Health and Hospitals System Chicago, Illinois   MedicalResearch.com: What is the background for this study? Response: This study was performed in the backdrop of recent colorectal cancer screening guideline updates.  Two national organizations are recommending screening initiation at two different ages: USPSTF recommends initiation at age 45 and the American College of Physicians (ACP) recommends initiation at age 50. With now two national organizations recommending different ages to start screening, patients may become confused (particularly those between 45-50).  Prior confusion has been documented when breast cancer screening recommendations were being changed as well.  Our focus was to examine colorectal adenocarcinoma incidence rates with stage stratification of those who are between the ACP and USPSTF recommendations (ages 46-49). Our study utilized SEER17 data registries over 2000-2020 to collect incidence rates within the U.S.  (more…)
Author Interviews, Cancer Research, Microbiome / 07.03.2024

MedicalResearch.com Interview with: Dr Ashray Gunjur MBBS (Hons), B. Med Sci, MPHTM FRACP Clinical Research Training Fellow Melbourne, Australia   MedicalResearch.com: What is the background for this study? Response: As background, the last ~5 years have seen a surge of interest in the relationship between gut microbiota and cancer response to immune checkpoint blockade (ICB). We know that though a fraction of many different cancer types will respond to these therapies, it is currently very hard to predict who that will be- so ‘microbiome’ based biomarkers to select patients, or even strategies to change a patient’s microbiome to enhance their chance of responding, are very attractive. A key challenge, however, has been a lack of consistency in the microbes associated with response or non-response across different studies from different regions. While geographic, methodological, and technical variation likely contribute to this, most studies examined the gut microbiome at a genus- or species- taxonomic rank level, while we know there is significant intra-species (strain-level) diversity. As such, one of our key research questions was whether we could improve the reproducibility of microbial ‘signatures’ of response across cohorts using higher resolution approaches- with our hypothesis being that strain-resolution signatures would outperform species- or lower resolution signatures. We obtained our signature by analysing baseline faecal samples from the CA209-538 clinical trial, a wonderful investigator-initiated study sponsored by the Olivia Newton-John Cancer Research Institute (Melbourne, Australia). I was fortunate enough to work on this trial as a clinical investigator while training to be a medical oncologist. (more…)
Cancer Research, Social Issues / 05.03.2024

Caring for a spouse battling cancer presents unique challenges, often requiring a delicate balance of physical, emotional, and logistical support. Providing care in the comfort of a home can offer a sense of familiarity and warmth during a challenging time. The aim must be to create a supportive environment, manage medical needs, and seek emotional support. It will empower spouses as they embark on this journey of care and compassion. According to the AACR Cancer Progress Report, cancer survivors have significantly improved from 50 years ago. It constituted only 1.4 percent of the US population earlier, but they have increased considerably. The number of cancer survivors is estimated to grow to 26 million by 2040. All they need is proper treatment and support to battle it. In this article, we'll delve into effective approaches and available aids for spouses managing the intricate challenges of caring for cancer patients. These insights and resources aim to enhance the quality of life for their beloved partners while safeguarding their own health and wellness.

Establishing a Supportive Environment

When caring for a wife with cancer at home, it is paramount to establish a supportive environment for her. It includes creating a calm and comfortable space that promotes relaxation. Ensure the environment is clean, organized, and free from clutter. Additionally, it's essential to maintain open communication with healthcare providers and loved ones to coordinate care effectively. Establishing a routine that accommodates the wife's and the caregiver's needs will create a sense of predictability and stability. It is crucial during this challenging time. (more…)
Author Interviews, Breast Cancer, Cancer Research / 04.02.2024

MedicalResearch.com Interview with: Takemi Tanaka, Ph. D. Professor, Stephenson Cancer Center Department of Pathology, School of Medicine University of Oklahoma Health Science Center MedicalResearch.com: What is the background for this study? Response: Our previous cohort study has shown that breast cancer progresses 60 days after diagnostic biopsy in early-stage ER+ breast cancer. Others have also reported increased breast cancer mortality due to surgery delay. These observations raised the question of how slow-growing ER+ breast cancer progresses so quickly in just 60 days following diagnosis, prompting us to hypothesize whether needle biopsy of breast tumors accelerates pro-metastatic changes. (more…)
Author Interviews, Cancer Research, Case Western, Colon Cancer, JAMA / 07.12.2023

MedicalResearch.com Interview with: Nathan A. Berger, M.D. Distinguished University ProfessorHanna-Payne Professor of Experimental MedicineProfessor of Medicine, Biochemistry, Oncology and GeneticsDirector, Center for Science, Health and SocietyCase Western Reserve University School of Medicine   Rong Xu, PhD Professor, Biomedical Informatics Director, Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine     MedicalResearch.com: What is the background for this study? Response: 75% of the US Population has overweight or obesity and 15% has Type 2 Diabetes. Both overweight/obesity and diabetes promote increased incidence and worse prognosis of colorectal cancer. The new GLP1RA drug class are rapidly becoming the most effective treatment for both diabetes and overweight/obesity. By controlling diabetes and overweight/obesity, we hypothesized that the GLP1RAs might be effective at reducing incidence of colorectal cancer. (more…)
Author Interviews, Cancer Research, Cost of Health Care, JAMA, Pharmacology / 17.11.2023

MedicalResearch.com Interview with: Lisa-Marie Smale, PharmD PhD Candidate Clinical Pharmacy Radboud University Medical Center Department of Pharmacy Nijmegen, the Netherlands Lisa-Marie Smale, PharmDPhD Candidate Clinical PharmacyRadboud University Medical CenterDepartment of PharmacyNijmegen, the Netherlands   MedicalResearch.com: What is the background for this study? Response: Cancer drugs are not always fully used by patients, while these drugs are mostly expensive and environmentally damaging, both in production and (waste) disposal. Therefore we investigated whether unused drugs of patients can be collected, verified of quality by a pharmacy, to be redispensed to other patients instead of being disposed of. We were interested whether such an approach ultimately leads to lower environmental impacts and costs. (more…)
Author Interviews, Cancer Research, JAMA, Lung Cancer, NIH, Race/Ethnic Diversity, Stanford / 01.11.2023

MedicalResearch.com Interview with: Summer S Han, PhD Associate Professor Quantitative Sciences Unit Stanford Center for Biomedical Informatics Research (BMIR) Department of Neurosurgery and Department of Medicine Department of Epidemiology & Population Health (by Courtesy) Stanford University School of Medicine Dr. Eunji Choi PhD Instructor, Neurosurgery Department: Adult Neurosurgery Stanford University School of Medicine   MedicalResearch.com: What is the background for this study?
  • Lung cancer is the leading cause of cancer death in the United States, killing about 127,000 people annually, but it can be treatable if detected early.
  • Low-dose computed tomography, or CT scan, has been shown to significantly reduce the number of lung cancer deaths. But because the radiation delivered by the scans can be harmful (they use on average about 10 times the radiation of standard X-rays), only those people at relatively high risk for lung cancer should be screened. The two biggest risk factors for lung cancer are exposure to tobacco smoke and age. Current national guidelines that rely on age and smoking exposure to recommend people for lung cancer screening are disproportionally failing minority populations including African Americans, according to a new study led by researchers at Stanford Medicine.
  • In 2021, the national guidelines by the U.S. Preventive Services Task Force (USPSTF) issued revised recommendation guidelines on lung cancer screening, lowering the start age from 55-year to 50-year and the smoking pack-year criterion from 30 to 20, compared to the 2013 USPSTF criteria. In comparison to the 2013 criteria, the new modifications have been shown to lessen racial disparities in screening eligibility between African Americans and Whites. However, potential disparities across other major racial groups in the U.S., such as Latinos, remains poorly examined.
  • Meanwhile, risk prediction model assesses a person’s risk score of developing an illness, such as lung cancer.
(more…)
Author Interviews, Environmental Risks, Thyroid / 27.10.2023

MedicalResearch.com Interview with: Maaike van Gerwen, MD, PhD Assistant Professor Department of Otolaryngology- Head and Neck Surgery Institute for Translational Epidemiolog Director of Research Department of Otolaryngology- Head and Neck Surgery Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Where are these PFAS chemicals found? Response: Over the past decades, we have seen an increasing trend in thyroid cancer which cannot be fully explained by increased use of medical imaging (including ultrasound). Certain environmental exposure are known to impact on the thyroid gland, including thyroid dysfunction or development of cancer. PFAS are chemicals that are known to disrupt the function of endocrine organs, such as the thyroid gland. We therefore hypothesized that PFAS exposure may be one of the potential risk factors for thyroid cancer and thus one of the potential reason for the increasing thyroid cancer incidence. PFAS chemicals are widespread in the environment and have been found in the soil, water, and air. PFAS are also widely used in a variety of consumer products including non-stick cookware, stain resisting fabric, firefighting foams, but are also found in drinking water and food. This leads to an almost universal exposure of the general population. (more…)
Breast Cancer, Technology / 22.10.2023

Breast cancer accounts for 12.5% of new annual cases in the world, making it the most common of all cancers. Early detection is vital, since when breast cancer is localized, it boasts a 99% survival rate. Despite this fact, only 64% of breast cancer cases are detected at a localized stage in the US, according to data obtained from the National Breast Cancer Foundation. The good news is that scientists at MIT have developed a new device that can simply be incorporated into a bra. Doing so would allow more frequent monitoring of people with a high risk for breast cancer and it would enable women to detect very early stage tumors.
A Patch In Time
The device is a flexible patch that can be attached to any bra. It has an ultrasound tracker that can analyze breast tissue from various angles—and the images obtained are as high in quality as those obtained from ultrasound probes used in medical imaging clinics The device provides real-time information that is easy to access and interpret. The development of the device resulted from the personal experience of MIT associate professor. Canan Dagdeviren. The latter’s aunt was diagnosed with late-stage breast cancer at the age of 49, passing away six months later. While sitting by her aunt’s bedside, the researchers created a rough schematic of a diagnostic patch that could be incorporated into a brassiere. The aim was to enable women to obtain more frequent information instead of depending on a once-yearly (or less frequent) checkup. Dagdeviren’s device is essentially a miniature 3D-printed ultrasound scanner that has tiny openings. It can be rotated to obtain images from a plethora of angles, and does not require medical expertise to use. The device leverages the very latest technology, including AI algorithms, biomedical systems, and low-power circuits
(more…)
Author Interviews, Genetic Research, Melanoma / 06.10.2023

MedicalResearch.com Interview with: Dr Mitchell Stark B.App.Sc (Hons), PhD UQ Amplify Senior Research Fellow Skin Cancer Genomics and Biomarker Discovery Group Leader Frazer Institute Faculty of Medicine The University of Queensland Translational Research Institute Woolloongabba, QLD 4102   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Nodular melanoma (NM) is one of the most aggressive subtypes of melanoma. Despite making up only 14 per cent of cases, it is the largest contributor to melanoma deaths. Nodular melanoma is difficult to catch early because it grows fast and has often spread deeper in the skin by the time it’s diagnosed. Around a quarter of NM cases also appear as a skin-coloured tumour, which might go unnoticed for longer. In this study we wanted to determine whether there were genetic variants associated with nodular melanoma, which might contribute to nodular melanoma risk. We identified 39 genes with rare DNA variants which had the greatest frequency in nodular melanoma patients compared to non-NM patients. (more…)